Business, energy, technology, markets and global industry news from Business News Today

The Lancet

PharmaDeviceNews The Lancet
A representative image illustrating Capricor Therapeutics’ deramiocel Duchenne muscular dystrophy program as the FDA extends its review to November 22, 2026, while new HOPE-3 data strengthen the company’s case around preservation of upper limb function.
Pharma & Biotech

Deramiocel gets three more months at FDA as Capricor shifts Duchenne approval case to arm function

FDA extends deramiocel review to November 22 as Capricor submits new HOPE-3 data supporting an upper limb function indication in Duchenne.

Read More
Representative image of neuroscience and gene therapy research, reflecting Taysha Gene Therapies’ TSHA-102 Rett syndrome update and the race to develop disease-modifying treatments for rare neurodevelopmental disorders.
Pharma & Biotech

Why Taysha’s Rett syndrome data could become a major gene therapy test case

Find out how Taysha’s TSHA-102 Rett syndrome update could shape gene therapy development, BLA planning and future disease-modifying care.

Read More
Pharma & Biotech

Regeneron’s cemdisiran enters FDA and EMA review for generalized myasthenia gravis

Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis care with potential quarterly subcutaneous dosing.

Read More
Representative image of a lung cancer treatment setting, as OptiTROP-Lung05 data put sacituzumab tirumotecan at the centre of the first-line NSCLC immunotherapy debate.
Pharma & Biotech

Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?

A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.

Read More